{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-002309","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2024-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.534054+00:00","generated_at":"2026-06-05T04:50:28.293075+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Passage Bio reports FY2023 net loss of $102.1M, appoints Kathleen Borthwick as CFO; cash runway into Q4 2025","bullets":["Cash, cash equivalents and marketable securities $114.3M as of Dec 31, 2023; cash runway expected into Q4 2025.","FY2023 net loss $102.1M ($1.86 per share); FY2022 net loss $136.1M ($2.50 per share).","Kathleen Borthwick appointed as permanent CFO effective March 1, 2024; base salary $422,240 plus options.","PBFT02 for FTD-GRN shows CSF progranulin elevated to supraphysiologic levels; cohort 1 dosing completion expected 1H 2024.","Company evaluating PBFT02 for FTD-C9orf72, ALS, and Alzheimer's; seeking regulatory feedback in 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-002309","json":"https://secwatch.observer/filing/0001558370-24-002309.json","markdown":"https://secwatch.observer/filing/0001558370-24-002309.md","text":"https://secwatch.observer/filing/0001558370-24-002309.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000155837024002309/0001558370-24-002309-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000155837024002309/pasg-20240304x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:50:28.293075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"80b29266975c0e65b21d76f0c616d2d72748c71f","claim":"Passage BIO, Inc. reported Quarter ended December 31, 2023 results: net income Net loss was $16.8 million, or $0.30 per basic and diluted share, for the quarter ended December 31, 2023.","evidence_excerpt":"Net loss was $16.8 million, or $0.30 per basic and diluted share, for the quarter ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000155837024002309/0001558370-24-002309-index.htm","confidence":0.96,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Quarter ended December 31, 2023"},{"label":"Net income","value":"Net loss was $16.8 million, or $0.30 per basic and diluted share, for the quarter ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b994aa7b8e68a7569459739d9afb1d0e72668f36","claim":"Passage BIO, Inc. reported Year ended December 31, 2023 results: net income Net loss was $16.8 million, or $0.30 per basic and diluted share, for the quarter ended December 31, 2023 and $102.1 mil.","evidence_excerpt":"Net loss was $16.8 million, or $0.30 per basic and diluted share, for the quarter ended December 31, 2023 and $102.1 million, or $1.86 per basic and diluted share, for the year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000155837024002309/0001558370-24-002309-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Year ended December 31, 2023"},{"label":"Net income","value":"Net loss was $16.8 million, or $0.30 per basic and diluted share, for the quarter ended December 31, 2023 and $102.1 mil"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d6148f5964320d53d2c32b18642ade37bfacc4c3","claim":"Passage BIO, Inc. reported Fourth Quarter and Full-Year 2023 results: net income Net loss was $16.8 million, or $0.30 per basic and diluted share, for the quarter ended December 31, 2023 and $102.1 mil.","evidence_excerpt":"Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000155837024002309/0001558370-24-002309-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter and Full-Year 2023"},{"label":"Net income","value":"Net loss was $16.8 million, or $0.30 per basic and diluted share, for the quarter ended December 31, 2023 and $102.1 mil"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d659fc5a3f","claim":"Kathleen Borthwick was appointed as Chief Financial Officer at Passage BIO, Inc..","evidence_excerpt":"On March 1, 2024 (the “Effective Date”), Kathleen Borthwick, the Company’s current Senior Vice President and Interim Chief Financial Officer was appointed to serve as Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000155837024002309/0001558370-24-002309-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}